PT Ekadharma International (EKAD) Fundamentals 2026 — P/E 11.8x, Revenue Analysis | SniperIQ
PT Ekadharma International (EKAD) is a ID-listed Basic Materials company in Chemicals - Specialty with a market capitalization of Rp590.5B, trading at Rp169.00 on the JKT. This SniperIQ fundamentals page covers PT Ekadharma International's valuation (P/E 11.8x, P/B 0.5x), profitability (net margin 9.2%), revenue (Rp529.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is PT Ekadharma International's market cap?
PT Ekadharma International (EKAD) has a market capitalization of approximately Rp590.5B, trading at Rp169.00 on the JKT. Market cap moves with the live share price.
What is PT Ekadharma International's P/E ratio?
PT Ekadharma International's trailing twelve-month P/E ratio is 11.8x, with a price-to-book (P/B) of 0.5x. Valuation multiples are best compared with Basic Materials sector peers rather than read in isolation.
How profitable is PT Ekadharma International?
PT Ekadharma International runs a net profit margin of 9.2%, a gross margin of 27.9%, and an operating margin of 9.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does PT Ekadharma International generate?
PT Ekadharma International reported revenue of Rp529.5B for fiscal year 2025, with net income of Rp53.0B and earnings per share (EPS) of 15.18. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does PT Ekadharma International pay a dividend?
PT Ekadharma International offers a trailing dividend yield of about 5.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is PT Ekadharma International financially healthy?
PT Ekadharma International carries a debt-to-equity ratio of 0.02x and a current ratio of 20.28x, with a market beta of 0.01. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is PT Ekadharma International a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PT Ekadharma International (EKAD) the key facts are: market cap Rp590.5B, P/E 11.8x, revenue Rp529.5B, 52-week range 143-228. Weigh valuation, profitability, growth, and balance-sheet strength against Basic Materials peers and form your own view.
Track PT Ekadharma International's full fundamentals live
Get PT Ekadharma International's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.